Ella Willenbacher

1.6k total citations
32 papers, 735 citations indexed

About

Ella Willenbacher is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ella Willenbacher has authored 32 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 14 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Ella Willenbacher's work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Ella Willenbacher is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Ella Willenbacher collaborates with scholars based in Austria, Germany and United States. Ella Willenbacher's co-authors include Richard Greil, Wolfgang Willenbacher, Andrea Brunner, Karin Jöhrer, R. Biedermann, Claudia Zelle‐Rieser, Shanmugapriya Thangavadivel, Patrizia Stoitzner, Dominik Wolf‎ and Andreas Seeber and has published in prestigious journals such as Blood, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Ella Willenbacher

31 papers receiving 724 citations

Peers

Countries citing papers authored by Ella Willenbacher

Since Specialization

Citations

This map shows the geographic impact of Ella Willenbacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ella Willenbacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ella Willenbacher more than expected).

Fields of papers citing papers by Ella Willenbacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ella Willenbacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ella Willenbacher. The network helps show where Ella Willenbacher may publish in the future.

Co-authorship network of co-authors of Ella Willenbacher

This figure shows the co-authorship network connecting the top 25 collaborators of Ella Willenbacher. A scholar is included among the top collaborators of Ella Willenbacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ella Willenbacher. Ella Willenbacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation 2023 ·Annals of Hematology ·(unknown), Gudrun C. Thurner, Wolfgang Willenbacher, Margot Haun, Bettina Zelger, Ella Willenbacher	1
2	Deep learning analysis of mid‐infrared microscopic imaging data for the diagnosis and classification of human lymphomas 2023 ·Journal of Biophotonics ·(unknown), Andrea Brunner, B. Zelger, Ella Willenbacher, (unknown), Roland Stalder, Christian W. Huck, Wolfgang Willenbacher, Johannes Dominikus Pallua	3
3	Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study 2023 ·Journal of Medical Internet Research ·Jens Lehmann, Kelly M. de Ligt, (unknown), Johannes M. Giesinger, Monika Sztankay, (unknown), Lonneke V. van de Poll‐Franse, Gerhard Rumpold, (unknown), Ella Willenbacher, Wolfgang Willenbacher, Bernhard Holzner	6
4	Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR) 2023 ·Cancers ·Magdalena Benda, Hanno Ulmer, (unknown), (unknown), (unknown), Petra Pichler, Thomas Winder, Bernd Hartmann, (unknown), Maria Theresa Krauth, Hermine Agis, (unknown), Klaus Podar, Wolfgang Willenbacher, Ella Willenbacher	7
5	Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry 2022 ·Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy ·Alexander Brunner, Ella Willenbacher, Wolfgang Willenbacher, B. Zelger, (unknown), Christian W. Huck, Johannes Dominikus Pallua	2
6	Application of mid‐infrared microscopic imaging for the diagnosis and classification of human lymphomas 2021 ·Journal of Biophotonics ·Ella Willenbacher, Andrea Brunner, Bettina Zelger, Seraphin Hubert Unterberger, Roland Stalder, Christian W. Huck, Wolfgang Willenbacher, Johannes Dominikus Pallua	10
7	Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: A pilot study using the Ki67 proliferation index as an example 2020 ·Experimental Hematology ·Ella Willenbacher, Andrea Brunner, Wolfgang Willenbacher, Bettina Zelger, Dominik Wolf‎, Derek Rogge, Michelle C. Tappert, Johannes Dominikus Pallua	8
8	Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas 2020 ·Annals of Hematology ·Ella Willenbacher, Wolfgang Willenbacher, (unknown), (unknown), Claudia Manzl, Andrea Brunner	5
9	Curcumin: New Insights into an Ancient Ingredient against Cancer 2019 ·International Journal of Molecular Sciences ·Ella Willenbacher, Shah Zeb Khan, (unknown), Dario Trapani, (unknown), Dominik Wolf‎, Wolfgang Willenbacher, Gilbert Spizzo, Andreas Seeber	121
10	Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia 2019 ·Annals of Hematology ·Ella Willenbacher, Karin Jöhrer, Wolfgang Willenbacher, (unknown), Richard Greil, Brigitte Kircher	2
11	Short overview on the current standard of treatment in newly diagnosed multiple myeloma 2018 ·memo - Magazine of European Medical Oncology ·Ella Willenbacher, (unknown), Wolfgang Willenbacher	9
12	Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study 2018 ·BMC Cancer ·Marlies Antlanger, (unknown), Thomas Reiter, Alexandra Böhm, Wolfgang Lamm, (unknown), Ella Willenbacher, David Nachbaur, (unknown), Werner Rabitsch, Susanne Rasoul‐Rockenschaub, Nina Worel, Daniel Lechner, Hildegard Greinix, Felix Keil, Heinz Gisslinger, Hermine Agis, Maria‐Theresa Krauth	19
13	Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results 2018 ·Blood ·Heinz Gisslinger, Veronika Buxhofer‐Ausch, Josef Thaler, (unknown), Ella Willenbacher, Dominik Wolf‎, Róbert Královics, Bettina Gisslinger, (unknown), Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Martin Schalling, Maria‐Theresa Krauth, Richard Greil, Pavla Kadlecová, (unknown), Victoria Empson, Barbara Grohmann-Izay, Christoph Klade	12
14	Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics 2016 ·PLoS ONE ·Ella Willenbacher, (unknown), Ursula Rochau, Uwe Siebert, Wolfgang Willenbacher, (unknown)	16
15	Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR) 2016 ·Leukemia & lymphoma ·Wolfgang Willenbacher, Shanmugapriya Thangavadivel, Richard Greil, Ella Willenbacher, (unknown), Claudia Manzl, Karin Jöhrer, Andrea Brunner	4
16	Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example 2015 ·Critical Reviews in Oncology/Hematology ·Ursula Rochau, Beate Jahn, (unknown), Emily A. Burger, Christina Kurzthaler, (unknown), Ella Willenbacher, Guenther Gastl, Wolfgang Willenbacher, Uwe Siebert	12
17	Low Beclin-1 expression predicts improved overall survival in patients treated with immune-modulatory drugs for Multiple Myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: An analysis from the Austrian Myeloma Registry (AMR) 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Wolfgang Willenbacher, Ella Willenbacher, Claudia Zelle‐Rieser, R. Biedermann, (unknown), (unknown), (unknown)	1
18	Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells 2013 ·Haematologica ·(unknown), Zoltán Bánki, G. Carl Huber, Asim Ejaz, Brigitte Müllauer, Ella Willenbacher, Michael Steurer, Heribert Stoiber	26
19	Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity 2013 ·Leukemia ·(unknown), Zoltán Bánki, G. Carl Huber, Asim Ejaz, (unknown), (unknown), Ella Willenbacher, Michael Steurer, Heribert Stoiber	41
20	Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie 2012 ·Haematologica ·Marlene Troch, Barbara Kiesewetter, Wolfgang Willenbacher, Ella Willenbacher, Armin Zebisch, Werner Linkesch, Michael Fridrik, Leonhard Müllauer, Richard Greil, Markus Raderer	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact